APO Research
Talk to an analyst

APO RESEARCH · REPORT

CINV Existing and Pipeline Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global CINV Existing and Pipeline Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025186 pages

Choose your research edition.

Industry ResearchCINV Existing and Pipeline Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CINV Existing and Pipeline Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal CINV Existing and Pipeline Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CINV Existing and Pipeline Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CINV Existing and Pipeline Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CINV Existing and Pipeline Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CINV Existing and Pipeline Drugs include Merck, GlaxoSmithKline, Tesaro, Heron Therapeutics and Helsinn, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CINV Existing and Pipeline Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CINV Existing and Pipeline Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CINV Existing and Pipeline Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CINV Existing and Pipeline Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

CINV Existing and Pipeline Drugs Segment by Company

Merck

GlaxoSmithKline

Tesaro

Heron Therapeutics

Helsinn

CINV Existing and Pipeline Drugs Segment by Type

Akynzeo

Aloxi

Emend

Kytril Generic

Rolapitant

SUSTOL

Zofran Generic

CINV Existing and Pipeline Drugs Segment by Application

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Hospitals

Drugstores

CINV Existing and Pipeline Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CINV Existing and Pipeline Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CINV Existing and Pipeline Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CINV Existing and Pipeline Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CINV Existing and Pipeline Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. CINV Existing and Pipeline Drugs Industry Trends Table 2. CINV Existing and Pipeline Drugs Industry Drivers Table 3. CINV Existing and Pipeline Drugs Industry Opportunities and Challenges Table 4. CINV Existing and Pipeline Drugs Industry Restraints Table 5. Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global CINV Existing and Pipeline Drugs Sales by Manufacturers (Kg) & (2021-2026) Table 8. Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers Table 9. Global CINV Existing and Pipeline Drugs Average Sales Price (US$/Kg) of Manufacturers (2021-2026) Table 10. Global CINV Existing and Pipeline Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global CINV Existing and Pipeline Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global CINV Existing and Pipeline Drugs Manufacturers, Product Type & Application Table 13. Global CINV Existing and Pipeline Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global CINV Existing and Pipeline Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Akynzeo Table 17. Major Manufacturers of Aloxi Table 18. Major Manufacturers of Emend Table 19. Major Manufacturers of Kytril Generic Table 20. Major Manufacturers of Rolapitant Table 21. Major Manufacturers of SUSTOL Table 22. Major Manufacturers of Zofran Generic Table 23. Global CINV Existing and Pipeline Drugs Sales by Type 2021 VS 2025 VS 2032 (Kg) Table 24. Global CINV Existing and Pipeline Drugs Sales by Type (2021-2026) & (Kg) Table 25. Global CINV Existing and Pipeline Drugs Sales by Type (2027-2032) & (Kg) Table 26. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2021-2026) Table 27. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2027-2032) Table 28. Global CINV Existing and Pipeline Drugs Revenue by Type 2021 VS 2025 VS 2032 (Kg) Table 29. Global CINV Existing and Pipeline Drugs Revenue by Type (2021-2026) & (Kg) Table 30. Global CINV Existing and Pipeline Drugs Revenue by Type (2027-2032) & (Kg) Table 31. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2021-2026) Table 32. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Specialty Clinics Table 34. Major Manufacturers of Diagnostic Centers Therapeutics Table 35. Major Manufacturers of Hospital Pharmacies Table 36. Major Manufacturers of Hospitals Table 37. Major Manufacturers of Drugstores Table 38. Global CINV Existing and Pipeline Drugs Sales by Application 2021 VS 2025 VS 2032 (Kg) Table 39. Global CINV Existing and Pipeline Drugs Sales by Application (2021-2026) & (Kg) Table 40. Global CINV Existing and Pipeline Drugs Sales by Application (2027-2032) & (Kg) Table 41. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2021-2026) Table 42. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2027-2032) Table 43. Global CINV Existing and Pipeline Drugs Revenue by Application 2021 VS 2025 VS 2032 (Kg) Table 44. Global CINV Existing and Pipeline Drugs Revenue by Application (2021-2026) & (Kg) Table 45. Global CINV Existing and Pipeline Drugs Revenue by Application (2027-2032) & (Kg) Table 46. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2021-2026) Table 47. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2027-2032) Table 48. Global CINV Existing and Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 49. Global CINV Existing and Pipeline Drugs Sales by Region (2021-2026) & (Kg) Table 50. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2021-2026) Table 51. Global CINV Existing and Pipeline Drugs Sales Forecasted by Region (2027-2032) & (Kg) Table 52. Global CINV Existing and Pipeline Drugs Sales Forecasted Market Share by Region (2027-2032) Table 53. North America CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 54. North America CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 55. North America CINV Existing and Pipeline Drugs Sales by Country (2027-2032) & (Kg) Table 56. Europe CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 57. Europe CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 58. Europe CINV Existing and Pipeline Drugs Sales by Country (2027-2032) & (Kg) Table 59. Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 60. Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 61. Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2027-2032) & (Kg) Table 62. South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 63. South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 64. South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2027-2032) & (Kg) Table 65. Global CINV Existing and Pipeline Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global CINV Existing and Pipeline Drugs Revenue by Region (2021-2026) & (US$ Million) Table 67. Global CINV Existing and Pipeline Drugs Revenue by Region (2027-2032) & (US$ Million) Table 68. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2021-2026) Table 69. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2027-2032) Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck CINV Existing and Pipeline Drugs Sales (Kg), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck CINV Existing and Pipeline Drugs Product Portfolio Table 74. Merck Recent Development Table 75. GlaxoSmithKline Company Information Table 76. GlaxoSmithKline Business Overview Table 77. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio Table 79. GlaxoSmithKline Recent Development Table 80. Tesaro Company Information Table 81. Tesaro Business Overview Table 82. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Tesaro CINV Existing and Pipeline Drugs Product Portfolio Table 84. Tesaro Recent Development Table 85. Heron Therapeutics Company Information Table 86. Heron Therapeutics Business Overview Table 87. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio Table 89. Heron Therapeutics Recent Development Table 90. Helsinn Company Information Table 91. Helsinn Business Overview Table 92. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Price (US$/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Helsinn CINV Existing and Pipeline Drugs Product Portfolio Table 94. Helsinn Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. CINV Existing and Pipeline Drugs Distributors List Table 98. CINV Existing and Pipeline Drugs Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. CINV Existing and Pipeline Drugs Product Image Figure 2. Global CINV Existing and Pipeline Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CINV Existing and Pipeline Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global CINV Existing and Pipeline Drugs Sales (2021-2032) & (Kg) Figure 5. Global CINV Existing and Pipeline Drugs Average Price (US$/Kg) & (2021-2032) Figure 6. Global Top 5 and 10 CINV Existing and Pipeline Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Akynzeo Image Figure 9. Aloxi Image Figure 10. Emend Image Figure 11. Kytril Generic Image Figure 12. Rolapitant Image Figure 13. SUSTOL Image Figure 14. Zofran Generic Image Figure 15. Global CINV Existing and Pipeline Drugs Sales by Type (2021 VS 2025 VS 2032) & (Kg) Figure 16. Global CINV Existing and Pipeline Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2021-2032) Figure 18. Global CINV Existing and Pipeline Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Kg) Figure 19. Global CINV Existing and Pipeline Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2021-2032) Figure 21. Specialty Clinics Image Figure 22. Diagnostic Centers Therapeutics Image Figure 23. Hospital Pharmacies Image Figure 24. Hospitals Image Figure 25. Drugstores Image Figure 26. Global CINV Existing and Pipeline Drugs Sales by Application (2021 VS 2025 VS 2032) & (Kg) Figure 27. Global CINV Existing and Pipeline Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2021-2032) Figure 29. Global CINV Existing and Pipeline Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Kg) Figure 30. Global CINV Existing and Pipeline Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2021-2032) Figure 32. North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 33. North America CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2032) Figure 34. U.S. CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 35. Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 36. Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 37. Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 38. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2032) Figure 39. Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 40. France CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 41. U.K. CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 42. Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 43. Netherlands CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 44. Asia Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 45. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2032) Figure 46. China CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 47. Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 48. South Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 49. Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 50. India CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 51. Australia CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 52. South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 53. South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2032) Figure 54. Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 55. South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 56. Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 57. Turkey CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 58. Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 59. UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 60. Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 61. Chile CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 62. Global CINV Existing and Pipeline Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America CINV Existing and Pipeline Drugs Revenue (2021-2032) & (US$ Million) Figure 65. North America CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe CINV Existing and Pipeline Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Europe CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific CINV Existing and Pipeline Drugs Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa CINV Existing and Pipeline Drugs Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. CINV Existing and Pipeline Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. CINV Existing and Pipeline Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Akynzeo
  • Aloxi
  • Emend
  • Kytril Generic
  • Rolapitant
  • SUSTOL
  • Zofran Generic
Applications
  • Specialty Clinics
  • Diagnostic Centers Therapeutics
  • Hospital Pharmacies
  • Hospitals
  • Drugstores
Companies covered
  • Merck
  • GlaxoSmithKline
  • Tesaro
  • Heron Therapeutics
  • Helsinn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CINV Existing and Pipeline Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CINV Existing and Pipeline Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global CINV Existing and Pipeline Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global CINV Existing and Pipeline Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global CINV Existing and Pipeline Drugs Market Dynamics
  1. 2.1 CINV Existing and Pipeline Drugs Industry Trends
  2. 2.2 CINV Existing and Pipeline Drugs Industry Drivers
  3. 2.3 CINV Existing and Pipeline Drugs Industry Opportunities and Challenges
  4. 2.4 CINV Existing and Pipeline Drugs Industry Restraints
3 CINV Existing and Pipeline Drugs Market by Manufacturers
  1. 3.1 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global CINV Existing and Pipeline Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global CINV Existing and Pipeline Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global CINV Existing and Pipeline Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global CINV Existing and Pipeline Drugs Manufacturers, Product Type & Application
  7. 3.7 Global CINV Existing and Pipeline Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global CINV Existing and Pipeline Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 CINV Existing and Pipeline Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 CINV Existing and Pipeline Drugs Tier 1, Tier 2, and Tier 3
4 CINV Existing and Pipeline Drugs Market by Type
  1. 4.1 CINV Existing and Pipeline Drugs Type Introduction
  2. 4.1.1 Akynzeo
  3. 4.1.2 Aloxi
  4. 4.1.3 Emend
  5. 4.1.4 Kytril Generic
  6. 4.1.5 Rolapitant
  7. 4.1.6 SUSTOL
  8. 4.1.7 Zofran Generic
  9. 4.2 Global CINV Existing and Pipeline Drugs Sales by Type
  10. 4.2.1 Global CINV Existing and Pipeline Drugs Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global CINV Existing and Pipeline Drugs Sales by Type (2021-2032)
  12. 4.2.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2021-2032)
  13. 4.3 Global CINV Existing and Pipeline Drugs Revenue by Type
  14. 4.3.1 Global CINV Existing and Pipeline Drugs Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2021-2032)
  16. 4.3.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2021-2032)
5 CINV Existing and Pipeline Drugs Market by Application
  1. 5.1 CINV Existing and Pipeline Drugs Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Diagnostic Centers Therapeutics
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Hospitals
  6. 5.1.5 Drugstores
  7. 5.2 Global CINV Existing and Pipeline Drugs Sales by Application
  8. 5.2.1 Global CINV Existing and Pipeline Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CINV Existing and Pipeline Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global CINV Existing and Pipeline Drugs Revenue by Application
  12. 5.3.1 Global CINV Existing and Pipeline Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2021-2032)
6 Global CINV Existing and Pipeline Drugs Sales by Region
  1. 6.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CINV Existing and Pipeline Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global CINV Existing and Pipeline Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global CINV Existing and Pipeline Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global CINV Existing and Pipeline Drugs Revenue by Region
  1. 7.1 Global CINV Existing and Pipeline Drugs Revenue by Region
  2. 7.1.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global CINV Existing and Pipeline Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global CINV Existing and Pipeline Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America CINV Existing and Pipeline Drugs Revenue (2021-2032)
  8. 7.2.2 North America CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe CINV Existing and Pipeline Drugs Revenue (2021-2032)
  11. 7.3.2 Europe CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific CINV Existing and Pipeline Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa CINV Existing and Pipeline Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa CINV Existing and Pipeline Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Tesaro
  14. 8.3.1 Tesaro Company Information
  15. 8.3.2 Tesaro Business Overview
  16. 8.3.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
  18. 8.3.5 Tesaro Recent Developments
  19. 8.4 Heron Therapeutics
  20. 8.4.1 Heron Therapeutics Company Information
  21. 8.4.2 Heron Therapeutics Business Overview
  22. 8.4.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
  24. 8.4.5 Heron Therapeutics Recent Developments
  25. 8.5 Helsinn
  26. 8.5.1 Helsinn Company Information
  27. 8.5.2 Helsinn Business Overview
  28. 8.5.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
  30. 8.5.5 Helsinn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CINV Existing and Pipeline Drugs Value Chain Analysis
  2. 9.1.1 CINV Existing and Pipeline Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CINV Existing and Pipeline Drugs Production Mode & Process
  6. 9.2 CINV Existing and Pipeline Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CINV Existing and Pipeline Drugs Distributors
  9. 9.2.3 CINV Existing and Pipeline Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst